Related references
Note: Only part of the references are listed.Pathogenesis and Consequences of Uniparental Disomy in Cancer
Hideki Makishima et al.
CLINICAL CANCER RESEARCH (2011)
Higher Dosage of the Epidermal Growth Factor Receptor Mutant Allele in Lung Adenocarcinoma Correlates with Younger Age, Stage IV at Presentation, and Poorer Survival
Gerard J. Oakley et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
KRAS mutant allele-specific imbalance in lung adenocarcinoma
Simion I. Chiosea et al.
MODERN PATHOLOGY (2011)
EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations
Simion Chiosea et al.
HUMAN PATHOLOGY (2010)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
In Situ Evidence of KRAS Amplification and Association With Increased p21 Levels in Non-Small Cell Lung Carcinoma
Patrick L. Wagner et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Integrative Approach for Prioritizing Cancer Genes in Sporadic Colon Cancer
James F. Reid et al.
GENES CHROMOSOMES & CANCER (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
Antonio Jimeno et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma
Jehad Abubaker et al.
JOURNAL OF PATHOLOGY (2009)
Oncogenic Activating Mutations Are Associated with Local Copy Gain
Barmak Modrek et al.
MOLECULAR CANCER RESEARCH (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines
Jeet Gandhi et al.
PLOS ONE (2009)
Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells
Junichi Soh et al.
PLOS ONE (2009)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Frequent occurrence of uniparental disomy in colorectal cancer
Claus Lindbjerg Andersen et al.
CARCINOGENESIS (2007)
Loss of heterozygosity of Kras2 gene on 12p12-13 in Chinese colon carcinoma patients
Jun Wan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas:: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study
V. Bazan et al.
ANNALS OF ONCOLOGY (2005)
LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer
J Li et al.
ONCOGENE (2003)
Wildtype Kras2 can inhibit lung carcinogenesis in mice
ZQ Zhang et al.
NATURE GENETICS (2001)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
